Literature DB >> 2140846

Hormonal responses to fenfluramine in depressed and control subjects.

P Mitchell1, G Smythe.   

Abstract

To investigate central neurotransmitter function in depression, baseline levels of serum cortisol and prolactin and the responses of these hormones to the putative serotonin agonist fenfluramine (60 mg, oral) were examined in 27 depressed patients and 14 normal subjects. Baseline cortisol was significantly elevated (P less than 0.01) in depressed subjects, whilst baseline prolactin was significantly reduced (P = 0.01) after covarying for cortisol. Although there were no significant abnormalities in either the prolactin or the cortisol response to fenfluramine in the total depressed group, the peak increase in prolactin levels (delta PRL) was significantly reduced (P less than 0.05) in subjects with endogenous depression. Analysis of covariance demonstrated, however, that the reduced delta PRL was partially dependent upon the abnormal baseline prolactin and cortisol levels. These results indicate the necessity of accounting for these baseline effects when investigating hormonal responses to the putative serotonergic challenges. The abnormal baseline findings are consistent with increased central noradrenergic activity in depression.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2140846     DOI: 10.1016/0165-0327(90)90008-v

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  5 in total

1.  Postviral fatigue syndrome.

Authors:  D Curtis; T Bullock
Journal:  BMJ       Date:  1992-06-13

2.  Platelet monoamine oxidase B (MAO-B) activity and its relationship to DL-fenfluramine-induced prolactin response in healthy men.

Authors:  M Eriksson; U Berggren; C Fahlke; J Engel; J Balldin
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

3.  A neuroendocrine study of 5HT function in depression: evidence for biological mechanisms of endogenous and psychosocial causation.

Authors:  J F Deakin; I Pennell; A J Upadhyaya; R Lofthouse
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 4.  Corticosteroid-serotonin interactions in depression: a review of the human evidence.

Authors:  Richard J Porter; Peter Gallagher; Stuart Watson; Allan H Young
Journal:  Psychopharmacology (Berl)       Date:  2004-03-09       Impact factor: 4.530

Review 5.  New pharmacological treatments for the management of obesity.

Authors:  Ryan T Hurt; Jithinraj Edakkanambeth Varayil; Jon O Ebbert
Journal:  Curr Gastroenterol Rep       Date:  2014
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.